Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
about
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveNew developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumabPotent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration
P2860
Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@ast
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@en
type
label
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@ast
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@en
prefLabel
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@ast
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@en
P2860
P356
P1476
Obinutuzumab: a novel anti-CD2 ...... chronic lymphocytic leukemia.
@en
P2093
Arpita Shah
P2860
P304
P356
10.1177/1060028014543271
P407
P577
2014-07-18T00:00:00Z